Amazon launches GLP-1 weight loss program, promising 'fast, convenient' access

Amazon is expanding its presence in the weight loss market by launching a new GLP-1 management program through its primary care division, Amazon One Medical. The initiative integrates obesity treatment into routine healthcare with a combination of virtual and in-person visits, prescription management, and pharmacy fulfillment via Amazon Pharmacy. The program aims to treat weight management as a chronic condition, offering patients streamlined access to popular GLP-1 medications such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, with insured pricing starting as low as $25 per month. The program emphasizes convenience and affordability, leveraging Amazon’s extensive logistics network to provide same-day delivery of medications to patients in thousands of cities. For uninsured patients, oral GLP-1 drugs start at $149 per month, while injectable treatments begin at $299 monthly. Amazon also offers on-demand prescription renewals, with consultations available via messaging or video at competitive prices. This approach positions Amazon to disrupt the traditional pharmacy and obesity care markets by simplifying access and improving medication adherence through reliable, fast delivery and transparent pricing. Amazon’s entry into the GLP-1 weight loss space has prompted a negative market reaction among competitors, with shares of companies such as Hims & Hers Health, Viking Therapeutics, Amgen, and Septerna declining amid investor concerns over increased competition. The move underscores Amazon’s broader strategy to expand its footprint in healthcare by integrating services and leveraging its consumer reach and infrastructure. As obesity rates continue to rise globally, Amazon’s program could significantly influence how weight management treatments are accessed and delivered in the future.